Nektar Therapeutics (NASDAQ:NKTR) Insider Mark Andrew Wilson Sells 33,402 Shares

Nektar Therapeutics (NASDAQ:NKTR) insider Mark Andrew Wilson sold 33,402 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $0.90, for a total value of $30,061.80. Following the completion of the transaction, the insider now directly owns 351,892 shares in the company, valued at $316,702.80. The trade was a 8.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Nektar Therapeutics Stock Up 4.8 %

Nektar Therapeutics stock traded up $0.04 during mid-day trading on Thursday, reaching $0.95. The company had a trading volume of 1,090,568 shares, compared to its average volume of 1,787,199. The company has a 50 day moving average of $1.15 and a 200-day moving average of $1.22. Nektar Therapeutics has a 52 week low of $0.48 and a 52 week high of $1.93. The firm has a market cap of $175.46 million, a price-to-earnings ratio of -1.13 and a beta of 0.57.

Institutional Investors Weigh In On Nektar Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NKTR. SG Americas Securities LLC lifted its position in shares of Nektar Therapeutics by 30.4% in the 3rd quarter. SG Americas Securities LLC now owns 95,637 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 22,285 shares during the period. Victory Capital Management Inc. acquired a new position in shares of Nektar Therapeutics in the second quarter valued at $29,000. Valence8 US LP bought a new position in Nektar Therapeutics in the third quarter worth $34,000. Jane Street Group LLC boosted its stake in Nektar Therapeutics by 50.0% during the third quarter. Jane Street Group LLC now owns 91,470 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 30,481 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in Nektar Therapeutics in the 3rd quarter valued at $41,000. 75.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on NKTR. Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They issued an “overweight” rating and a $7.00 price target on the stock. HC Wainwright assumed coverage on shares of Nektar Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $6.50 target price on the stock. Finally, BTIG Research restated a “buy” rating and set a $4.00 price target on shares of Nektar Therapeutics in a report on Monday, September 30th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $4.10.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.